Enter Note Done
Go to previous page in this tab
Event
  • Continuing Education Course
  • Bookmark Icon
  • SR01: Harmonized Benchmark Dose Modeling for Risk Assessment Decision-Making
  • Schedule
    Notes
  • Set Timezone

Primary Endorser: Risk Assessment Specialty Section


Endorser(s): Biological Modeling Specialty Section


Endorser(s): Regulatory and Safety Evaluation Specialty Section


Benchmark dose (BMD) methodology is a quantitative dose-response modeling approach used to identify points of departure associated with defined levels of response. It has been widely accepted as a preferred alternative to the traditional no-observed-adverse-effect level (NOAEL) approach because it uses more information from the dose-response data, is less dependent on the specific dose spacing used in a study, and provides a stronger basis for characterizing statistical uncertainty.

As chemical risk assessment increasingly incorporates diverse evidence streams, including animal toxicology studies, epidemiological data, high-throughput screening results, genomic data, and new approach methodologies (NAMs), there is a growing need for harmonized BMD modeling strategies that can be applied consistently across different data and study types in terms of modeling procedures and BMD estimation. This course will provide a practical introduction to BMD modeling and its application in risk assessment decision-making. The course will include two presentations: a presentation on Bayesian Benchmark Dose Modeling (BBMD) approaches across data and study types and a presentation on the use of BMD modeling in public health reference value derivation. These presentations will be followed by a question-and-answer period.

The first presentation, “Bayesian Benchmark Dose (BMD) Modeling Across Data and Study Types: A Harmonized Strategy for Chemical Risk Assessment,” will introduce the BMD methodology and demonstrate how the BBMD system can be used to analyze dichotomous, continuous, and categorical dose-response data from toxicological, epidemiological, and genomic studies using harmonized procedures for model fitting, goodness-of-fit evaluation, model selection, uncertainty characterization, and model-averaged BMD analysis in a common Bayesian framework. The second presentation, “From Data to Decisions: Benchmark Dose Modeling in Public Health,” will use the derivation of human health reference values, including ATSDR minimal risk levels, as a case study to show how BMD-derived points of departure are integrated with duration and dosimetry adjustments, uncertainty factors, animal and human data, NAMs, and emerging quantitative uncertainty methods to support public health decision-making.

Session and Activity Type
Presentations